Based in Canada, Hyasynth is developing patent-pending enzymes, yeast cells and processes to biosynthesize cannabinoids in genetically engineered yeast. Canadian licensed cannabis producer, Organigram (OGI) invested $10M into the company to scale up commercial production. Organigram and Hyasynth have entered into an agreement that allows Organigram to purchase a significant quantity of cannabinoids produced by Hyasynth.